Lu Dai Data-verified
Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.
Researcher
faculty
Research Areas
Links
Biography and Research Information
OverviewAI-generated summary
Lu Dai's research investigates mechanisms of disease and the development of biotherapeutic products. Current work includes studying the role of microRNAs in oral squamous cell carcinoma tumorgenesis, specifically focusing on exosomal miR-31-5p and its impact on the large tumor suppressor 2-mediated Hippo signaling pathway. Dai also investigates the Fc galactosylation of immunoglobulin G and its effects on hexamerization and complement activation, as well as the persistence and efficacy of FcεRIγ-negative NK cells in multiple myeloma treatment.
Further research explores the use of advanced analytical techniques for biopharmaceutical quality control. This includes developing versatile liquid chromatography-mass spectrometry (LC-MS) workflows for identifying residual host cell proteins in biotherapeutic products and employing multi-attribute Raman spectroscopy (MARS) for real-time monitoring of quality attributes in formulated monoclonal antibody therapeutics during cell culture production. Additionally, Dai's work has examined the anti-hyperglycemic and anti-fibrotic effects of Dendrobium officinale polysaccharide via the miRNA-34a-5p/SIRT1 signaling pathway and investigated the role of LINC01224/ZNF91 in promoting stem cell-like properties and radioresistance in non-small cell lung cancer.
Metrics
- h-index: 34
- Publications: 301
- Citations: 3,461
Selected Publications
-
Recent Advances in Development of Kaposi's Sarcoma‐Associated Herpesvirus‐Latency‐Associated Nuclear Antigen Targeted Therapies (2025)
-
Developing new ceramide analogs against non-small cell lung cancer (NSCLC) (2024)
-
Human endogenous retrovirus type K encoded Np9 oncoprotein induces DNA damage response (2024)
-
Development of human endogenous retrovirus type K‐ related treatments for human diseases (2024)
-
Role of lymphatic endothelium specific hyaluronan receptor 1 in virus infection and associated diseases (2024)
-
Coinfections with additional oncoviruses in HPV+ individuals: Status, function and potential clinical implications (2024)
-
Echinomycin as a promising therapeutic agent against KSHV-related malignancies (2023)
Federal Grants 3 $687,500 total
Role of Macrophage Migration Inhibitory Factor (MIF) in KSHV-associated Malignancies
Development of O’PROTACs-based degraders targeting an oncogenic viral protein
Similar Researchers
Based on overlapping research topics